PE20080732A1 - Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos - Google Patents
Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesosInfo
- Publication number
- PE20080732A1 PE20080732A1 PE2007000980A PE2007000980A PE20080732A1 PE 20080732 A1 PE20080732 A1 PE 20080732A1 PE 2007000980 A PE2007000980 A PE 2007000980A PE 2007000980 A PE2007000980 A PE 2007000980A PE 20080732 A1 PE20080732 A1 PE 20080732A1
- Authority
- PE
- Peru
- Prior art keywords
- oxo
- pyrrolidinyl
- dioxaspiro
- benzyl carbamate
- acetamido
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title 1
- 108050000299 Chemokine receptor Proteins 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 4
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 abstract 4
- -1 (3S) -3 - (((BENZYLOXY) CARBONYL) AMINO) -2-OXO-1-PYRROLIDINYL Chemical class 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 abstract 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 102000004497 CCR2 Receptors Human genes 0.000 abstract 1
- 108010017312 CCR2 Receptors Proteins 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83423506P | 2006-07-28 | 2006-07-28 | |
| US89602607P | 2007-03-21 | 2007-03-21 | |
| US11/782,742 US7629351B2 (en) | 2006-07-28 | 2007-07-25 | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080732A1 true PE20080732A1 (es) | 2008-06-13 |
Family
ID=38829183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000980A PE20080732A1 (es) | 2006-07-28 | 2007-07-26 | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos |
Country Status (26)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7687508B2 (en) * | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US8383812B2 (en) * | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| KR20120135716A (ko) * | 2011-06-07 | 2012-12-17 | 한미사이언스 주식회사 | 이중대칭 구조의 퀴나졸린 유도체 화합물 및 이의 용도 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| TW201625255A (zh) * | 2014-07-17 | 2016-07-16 | 參天製藥股份有限公司 | 後眼部疾病之預防或治療劑 |
| DK3655395T3 (da) * | 2017-07-20 | 2022-03-07 | Bristol Myers Squibb Co | Fremgangsmåde til fremstilling af n-((1r,2s,sr)-5-(tert-butylamino)-2-((s)-3-(7- tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1- yl)cyclohexyl)acetamid |
| CN115677728A (zh) * | 2022-11-02 | 2023-02-03 | 成都科岭源医药技术有限公司 | 一种海鞘素类化合物中间体的制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6383082A (ja) | 1986-09-26 | 1988-04-13 | Takeda Chem Ind Ltd | テトラヒドロフランカルボン酸誘導体の製造法 |
| EP0550924A1 (en) | 1991-12-16 | 1993-07-14 | Merck & Co. Inc. | 2-Pyrrolidinone derivatives as HIV protease inhibitors |
| GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| UA51716C2 (uk) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
| US6054579A (en) | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| KR20010034442A (ko) | 1998-01-27 | 2001-04-25 | 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 | 치환된 옥소아자헤테로사이클릴 인자 Ｘａ 억제제 |
| PL342254A1 (en) | 1998-01-29 | 2001-06-04 | Aventis Pharm Prod Inc | Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound |
| US6492553B1 (en) | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| US6541208B1 (en) | 1998-03-17 | 2003-04-01 | University Of Maryland Biotechnology Institute | Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia |
| WO2001017992A1 (en) | 1999-09-09 | 2001-03-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
| US6974836B2 (en) * | 2000-12-20 | 2005-12-13 | Bristol-Myers Squibb Pharma Company | Diamines as modulators of chemokine receptor activity |
| US6706712B2 (en) * | 2000-12-20 | 2004-03-16 | Bristol-Myers Squibb Pharma Company | Cyclic derivatives as modulators of chemokine receptor activity |
| ATE318596T1 (de) | 2001-03-29 | 2006-03-15 | Topotarget As | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
| GB0114867D0 (en) | 2001-06-18 | 2001-08-08 | Merck Sharp & Dohme | Therapeutic agents |
| DE10135043A1 (de) * | 2001-07-11 | 2003-01-30 | Bayer Cropscience Gmbh | Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren |
| US7087604B2 (en) * | 2002-03-08 | 2006-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| WO2004022536A1 (en) | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| US6835841B2 (en) | 2002-09-13 | 2004-12-28 | Bristol-Myers Squibb Company | Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters |
| TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| US7338975B2 (en) * | 2003-02-12 | 2008-03-04 | Bristol-Myers Squibb Co. | Lactams as modulators of chemokine receptor activity |
| US7230133B2 (en) * | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
| US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US20060205761A1 (en) | 2003-06-06 | 2006-09-14 | Catherine Abbadie | Ccr-2 antagonists for treatment of neuropathic pain |
| US7351720B2 (en) | 2003-06-12 | 2008-04-01 | Bristol-Myers Squibb Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US20050043392A1 (en) * | 2003-08-21 | 2005-02-24 | Carter Percy H. | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
| TWI354664B (en) * | 2003-08-21 | 2011-12-21 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine rece |
| US7378409B2 (en) * | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7863317B2 (en) * | 2003-08-21 | 2011-01-04 | Bristol-Myers Squibb Company | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
| US7317019B2 (en) * | 2003-08-21 | 2008-01-08 | Bristol Myers Squibb Co. | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| CN101005855A (zh) | 2004-07-30 | 2007-07-25 | 辉瑞产品公司 | 治疗由ccr2介导的疾病或紊乱的方法 |
| MX2007003793A (es) * | 2004-09-28 | 2007-07-11 | Johnson & Johnson | Antagonistas del receptor 2 de citocina quimioatrayente de dipiperidina sustituida. |
| US7687508B2 (en) * | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
-
2007
- 2007-07-25 US US11/782,742 patent/US7629351B2/en active Active
- 2007-07-26 BR BRPI0715415-1A patent/BRPI0715415A2/pt not_active IP Right Cessation
- 2007-07-26 MX MX2009000808A patent/MX2009000808A/es active IP Right Grant
- 2007-07-26 AU AU2007279333A patent/AU2007279333B2/en not_active Ceased
- 2007-07-26 EP EP10001989A patent/EP2194051B1/en not_active Not-in-force
- 2007-07-26 PT PT07813363T patent/PT2046779E/pt unknown
- 2007-07-26 CN CN200780032859.9A patent/CN101535301B/zh not_active Expired - Fee Related
- 2007-07-26 WO PCT/US2007/074377 patent/WO2008014360A2/en not_active Ceased
- 2007-07-26 EA EA200900245A patent/EA016563B1/ru not_active IP Right Cessation
- 2007-07-26 DK DK07813363.4T patent/DK2046779T3/da active
- 2007-07-26 EP EP07813363A patent/EP2046779B1/en active Active
- 2007-07-26 NZ NZ574425A patent/NZ574425A/en not_active IP Right Cessation
- 2007-07-26 TW TW102141345A patent/TW201414729A/zh unknown
- 2007-07-26 JP JP2009522952A patent/JP5236643B2/ja not_active Expired - Fee Related
- 2007-07-26 KR KR1020097004311A patent/KR20090033915A/ko not_active Ceased
- 2007-07-26 TW TW096127304A patent/TWI421249B/zh not_active IP Right Cessation
- 2007-07-26 CA CA002659253A patent/CA2659253A1/en not_active Abandoned
- 2007-07-26 SI SI200730680T patent/SI2046779T1/sl unknown
- 2007-07-26 HR HR20110465T patent/HRP20110465T1/hr unknown
- 2007-07-26 SG SG201000703-7A patent/SG158924A1/en unknown
- 2007-07-26 PE PE2007000980A patent/PE20080732A1/es not_active Application Discontinuation
- 2007-07-26 AT AT07813363T patent/ATE509926T1/de active
- 2007-07-26 ES ES07813363T patent/ES2365264T3/es active Active
- 2007-07-26 AT AT10001989T patent/ATE522522T1/de not_active IP Right Cessation
- 2007-07-26 PL PL07813363T patent/PL2046779T3/pl unknown
- 2007-07-26 CA CA2831219A patent/CA2831219A1/en not_active Abandoned
- 2007-07-27 AR ARP070103332A patent/AR062124A1/es not_active Application Discontinuation
-
2009
- 2009-01-11 IL IL196427A patent/IL196427A/en not_active IP Right Cessation
- 2009-01-13 NO NO20090190A patent/NO20090190L/no not_active Application Discontinuation
- 2009-10-27 US US12/606,255 patent/US8049019B2/en active Active
-
2010
- 2010-06-28 IL IL206679A patent/IL206679A0/en unknown
-
2011
- 2011-08-05 CY CY20111100753T patent/CY1111744T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080732A1 (es) | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos | |
| CL2017003445A1 (es) | Formas solidas y formulaciones de compuestos de imidazopirazina. | |
| PE20220016A1 (es) | Inhibidores y metodos de uso de kcnt1 | |
| CL2010001486A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras. | |
| CR9505A (es) | Formas cristalinas anhidras de la n-(1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo(4,3-d)pirimidina-3-cabonil)metanosulfonamida | |
| HK1244483A1 (zh) | (s)-n-(5 - ((r)-2-(2，5-二氟苯基)吡咯烷-1-基) - 吡唑并[1，5-a ]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐 | |
| PE20240050A1 (es) | Inhibidores de cdk2 y metodos de uso de los mismos | |
| NO20082476L (no) | Bicykliske forbindelser med kinaseinhiberende aktivitet | |
| CL2008003023A1 (es) | (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer. | |
| CL2008001103A1 (es) | Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-corboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de megl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros. | |
| PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| MA44610A (fr) | Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| MXPA04008152A (es) | Compuestos azabiciclicos para el tratamiento de enfermedades. | |
| IL277904B1 (en) | Indene derivatives useful in treating pain and inflammation | |
| CO6460737A2 (es) | N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos | |
| PE20080838A1 (es) | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos | |
| PE20081308A1 (es) | Derivados ciclicos como moduladores de la actividad del receptor de quimiocina | |
| CY1109539T1 (el) | Χρηση 5'-μεθυλοθειοαδενοσινης (μτα) στην προληψη και/η θεραπεια αυτοανοσων νοσων και/η απορριψης μοσχευματων | |
| TW200716204A (en) | Pharmaceutical composition | |
| BRPI0617655A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica | |
| CL2008003358A1 (es) | Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos. | |
| IL276013B2 (en) | Pi4kiiibeta inhibitors | |
| BRPI0515954A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo e enanciÈmeros e diaestereÈmeros individuais do mesmo, composição farmacêutica, e, métodos para inibição do transportador de glicina glyt1 em um mamìfero, para a fabricação de um medicamento para inibir o transportador de glicina glyt1 em um mamìfero, para tratar um distúbios neurológicos e psiquiátricos associados com disfunçao de neurotransmissão glicinérgica ou glutamatérgica em um paciente mamìfero e para tratar esquizofrenia em um paciente mamìfero |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |